Recombinant
RabMAb

Recombinant Anti-VEGF Receptor 2 antibody [EPR21884-290] (ab221679)

Overview

  • Product name

    Anti-VEGF Receptor 2 antibody [EPR21884-290]
    See all VEGF Receptor 2 primary antibodies
  • Description

    Rabbit monoclonal [EPR21884-290] to VEGF Receptor 2
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Mouse, Rat
  • Immunogen

    Recombinant fragment within Mouse VEGF Receptor 2 aa 1-800. The exact sequence is proprietary.
    Database link: P35918

  • Positive control

    • WB: Mouse and rat placenta and lung lysates; bEnd.3 whole cell lysate.
  • General notes

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Applications

Our Abpromise guarantee covers the use of ab221679 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 180-230 kDa (predicted molecular weight: 152 kDa).

Target

  • Function

    Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in disease

    Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications

    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localization

    Membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • CD309 antibody
    • CD309 antigen antibody
    • EC 2.7.10.1 antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Images

  • All lanes : Anti-VEGF Receptor 2 antibody [EPR21884-290] (ab221679) at 1/1000 dilution

    Lane 1 : Mouse placenta lysate at 20 µg
    Lane 2 : Rat placenta lysate at 20 µg
    Lane 3 : Rat lung lysate at 20 µg
    Lane 4 : Mouse lung lysate at 20 µg
    Lane 5 : bEnd.3 (mouse brain endothelioma cell line) whole cell lysate at 10 µg

    Secondary
    Lanes 1-4 : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
    Lane 5 : VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution

    Developed using the ECL technique.

    Predicted band size: 152 kDa
    Observed band size: 180-230 kDa
    why is the actual band size different from the predicted?



    Exposure time :  Lanes 1-2: 3 minutes; Lane 3: 37 seconds; Lane 4: 59 seconds; Lane 5: 15 seconds

    The molecular mass observed is consistent with the literature (PMID: 23354168 ; PMID: 20606037).

References

ab221679 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab221679.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up